Search

Your search keyword '"Intlekofer, Andrew M"' showing total 341 results
Start Over Author "Intlekofer, Andrew M"
341 results on '"Intlekofer, Andrew M"'

1. Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes

Author

Lue, Jennifer K., Luttwak, Efrat, Rivas-Delgado, Alfredo, Irawan, Helen, Boardman, Alexander, Caron, Philip C., David, Kevin, Epstein-Peterson, Zachary, Falchi, Lorenzo, Ghione, Paola, Hamlin, Paul, Horwitz, Steven M., Intlekofer, Andrew M., Johnson, William, Kumar, Anita, Moskowitz, Alison, Noy, Ariela, Palomba, M. Lia, Steiner, Ralphael, Stuver, Robert, Torka, Pallawi, Vardhana, Santosha, Zelenetz, Andrew D., Schoder, Heiko, Imber, Brandon, Yahalom, Joachim, Zhang, Yanming, Galera, Pallavi, Dogan, Ahmet, Aypar, Umut, and Salles, Gilles

Published
2024
Full Text
View/download PDF

2. CD8+ T cell metabolic flexibility elicited by CD28-ARS2 axis-driven alternative splicing of PKM supports antitumor immunity

Author

Holling, G. Aaron, Chavel, Colin A., Sharda, Anand P., Lieberman, Mackenzie M., James, Caitlin M., Lightman, Shivana M., Tong, Jason H., Qiao, Guanxi, Emmons, Tiffany R., Giridharan, Thejaswini, Hou, Shengqi, Intlekofer, Andrew M., Higashi, Richard M., Fan, Teresa W. M., Lane, Andrew N., Eng, Kevin H., Segal, Brahm H., Repasky, Elizabeth A., Lee, Kelvin P., and Olejniczak, Scott H.

Published
2024
Full Text
View/download PDF

4. Retrospective characterization of nodal marginal zone lymphoma

Author

Stuver, Robert, Drill, Esther, Qualls, David, Okwali, Michelle, Lee Batlevi, Connie, Caron, Philip C., Dogan, Ahmet, Epstein-Peterson, Zachary D., Falchi, Lorenzo, Hamlin, Paul A., Horwitz, Steven M., Imber, Brandon S., Intlekofer, Andrew M., Johnson, William T., Khan, Niloufer, Kumar, Anita, Lahoud, Oscar B., Lue, Jennifer Kimberly, Matasar, Matthew J., Moskowitz, Alison J., Noy, Ariela, Owens, Colette N., Palomba, M. Lia, Schöder, Heiko, Vardhana, Santosha A., Yahalom, Joachim, Zelenetz, Andrew D., Salles, Gilles, and Straus, David J.

Published
2023
Full Text
View/download PDF

5. TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy

Author

Johnson, William T., Ganesan, Nivetha, Epstein-Peterson, Zachary D., Moskowitz, Alison J., Stuver, Robert N., Maccaro, Catherine R., Galasso, Natasha, Chang, Tiffany, Khan, Niloufer, Aypar, Umut, Lewis, Natasha E., Zelenetz, Andrew D., Palomba, M. Lia, Matasar, Matthew J., Noy, Ariela, Hamilton, Audrey M., Hamlin, Paul, Caron, Philip C., Straus, David J., Intlekofer, Andrew M., Lee Batlevi, Connie, Kumar, Anita, Owens, Colette N., Sauter, Craig S., Falchi, Lorenzo, Lue, Jennifer K., Vardhana, Santosha A., Salles, Gilles, Dogan, Ahmet, Schultz, Nikolaus D., Arcila, Maria E., and Horwitz, Steven M.

Published
2023
Full Text
View/download PDF

10. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice

Author

Townsend, Elizabeth C, Murakami, Mark A, Christodoulou, Alexandra, Christie, Amanda L, Köster, Johannes, DeSouza, Tiffany A, Morgan, Elizabeth A, Kallgren, Scott P, Liu, Huiyun, Wu, Shuo-Chieh, Plana, Olivia, Montero, Joan, Stevenson, Kristen E, Rao, Prakash, Vadhi, Raga, Andreeff, Michael, Armand, Philippe, Ballen, Karen K, Barzaghi-Rinaudo, Patrizia, Cahill, Sarah, Clark, Rachael A, Cooke, Vesselina G, Davids, Matthew S, DeAngelo, Daniel J, Dorfman, David M, Eaton, Hilary, Ebert, Benjamin L, Etchin, Julia, Firestone, Brant, Fisher, David C, Freedman, Arnold S, Galinsky, Ilene A, Gao, Hui, Garcia, Jacqueline S, Garnache-Ottou, Francine, Graubert, Timothy A, Gutierrez, Alejandro, Halilovic, Ensar, Harris, Marian H, Herbert, Zachary T, Horwitz, Steven M, Inghirami, Giorgio, Intlekofer, Andrew M, Ito, Moriko, Izraeli, Shai, Jacobsen, Eric D, Jacobson, Caron A, Jeay, Sébastien, Jeremias, Irmela, Kelliher, Michelle A, Koch, Raphael, Konopleva, Marina, Kopp, Nadja, Kornblau, Steven M, Kung, Andrew L, Kupper, Thomas S, LeBoeuf, Nicole R, LaCasce, Ann S, Lees, Emma, Li, Loretta S, Look, A Thomas, Murakami, Masato, Muschen, Markus, Neuberg, Donna, Ng, Samuel Y, Odejide, Oreofe O, Orkin, Stuart H, Paquette, Rachel R, Place, Andrew E, Roderick, Justine E, Ryan, Jeremy A, Sallan, Stephen E, Shoji, Brent, Silverman, Lewis B, Soiffer, Robert J, Steensma, David P, Stegmaier, Kimberly, Stone, Richard M, Tamburini, Jerome, Thorner, Aaron R, van Hummelen, Paul, Wadleigh, Martha, Wiesmann, Marion, Weng, Andrew P, Wuerthner, Jens U, Williams, David A, Wollison, Bruce M, Lane, Andrew A, Letai, Anthony, Bertagnolli, Monica M, Ritz, Jerome, Brown, Myles, Long, Henry, Aster, Jon C, Shipp, Margaret A, Griffin, James D, and Weinstock, David M

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Biotechnology, Clinical Trials and Supportive Activities, Orphan Drug, Clinical Research, Hematology, Cancer, Rare Diseases, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Good Health and Well Being, Animals, Antineoplastic Agents, Biomarkers, Tumor, Cell Lineage, Female, Gene Expression Profiling, Genes, p53, Heterografts, Humans, Internet, Isoquinolines, Leukemia, Leukemia, Experimental, Lymphoma, Male, Mice, Mice, Inbred NOD, Molecular Targeted Therapy, Neoplasm Proteins, Neoplasm Transplantation, Phenotype, Piperazines, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Proteome, Proto-Oncogene Proteins c-mdm2, Random Allocation, Randomized Controlled Trials as Topic, Research Design, Tissue Banks, Transcriptome, Xenograft Model Antitumor Assays, Neurosciences, Oncology & Carcinogenesis, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

More than 90% of drugs with preclinical activity fail in human trials, largely due to insufficient efficacy. We hypothesized that adequately powered trials of patient-derived xenografts (PDX) in mice could efficiently define therapeutic activity across heterogeneous tumors. To address this hypothesis, we established a large, publicly available repository of well-characterized leukemia and lymphoma PDXs that undergo orthotopic engraftment, called the Public Repository of Xenografts (PRoXe). PRoXe includes all de-identified information relevant to the primary specimens and the PDXs derived from them. Using this repository, we demonstrate that large studies of acute leukemia PDXs that mimic human randomized clinical trials can characterize drug efficacy and generate transcriptional, functional, and proteomic biomarkers in both treatment-naive and relapsed/refractory disease.

Published
2016

11. The epigenomics of sarcoma

Author

Nacev, Benjamin A., Jones, Kevin B., Intlekofer, Andrew M., Yu, Jamie S. E., Allis, C. David, Tap, William D., Ladanyi, Marc, and Nielsen, Torsten O.

Published
2020
Full Text
View/download PDF

12. Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis

Author

Yoshimi, Akihide, Lin, Kuan-Ting, Wiseman, Daniel H., Rahman, Mohammad Alinoor, Pastore, Alessandro, Wang, Bo, Lee, Stanley Chun-Wei, Micol, Jean-Baptiste, Zhang, Xiao Jing, de Botton, Stephane, Penard-Lacronique, Virginie, Stein, Eytan M., Cho, Hana, Miles, Rachel E., Inoue, Daichi, Albrecht, Todd R., Somervaille, Tim C. P., Batta, Kiran, Amaral, Fabio, Simeoni, Fabrizio, Wilks, Deepti P., Cargo, Catherine, Intlekofer, Andrew M., Levine, Ross L., Dvinge, Heidi, Bradley, Robert K., Wagner, Eric J., Krainer, Adrian R., and Abdel-Wahab, Omar

Published
2019
Full Text
View/download PDF

14. TP53mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy

Author

Johnson, William T., primary, Ganesan, Nivetha, additional, Epstein-Peterson, Zachary D., additional, Moskowitz, Alison J., additional, Stuver, Robert N., additional, Maccaro, Catherine R., additional, Galasso, Natasha, additional, Chang, Tiffany, additional, Khan, Niloufer, additional, Aypar, Umut, additional, Lewis, Natasha E., additional, Zelenetz, Andrew D., additional, Palomba, M. Lia, additional, Matasar, Matthew J., additional, Noy, Ariela, additional, Hamilton, Audrey M., additional, Hamlin, Paul, additional, Caron, Philip C., additional, Straus, David J., additional, Intlekofer, Andrew M., additional, Lee Batlevi, Connie, additional, Kumar, Anita, additional, Owens, Colette N., additional, Sauter, Craig S., additional, Falchi, Lorenzo, additional, Lue, Jennifer K., additional, Vardhana, Santosha A., additional, Salles, Gilles, additional, Dogan, Ahmet, additional, Schultz, Nikolaus D., additional, Arcila, Maria E., additional, and Horwitz, Steven M., additional

Published
2023
Full Text
View/download PDF

15. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations

Author

Intlekofer, Andrew M., Shih, Alan H., Wang, Bo, Nazir, Abbas, Rustenburg, Ariën S., Albanese, Steven K., and Patel, Minal

Subjects
Pharmaceutical research, Drug resistance -- Research, Antineoplastic agents -- Research, Genes, Alleles, Decitabine, Glutamine, Environmental issues, Science and technology, Zoology and wildlife conservation
Abstract

Somatic mutations in the isocitrate dehydrogenase 2 gene (IDH2) contribute to the pathogenesis of acute myeloid leukaemia (AML) through the production of the oncometabolite 2-hydroxyglutarate (2HG).sup.1-8. Enasidenib (AG-221) is an allosteric inhibitor that binds to the IDH2 dimer interface and blocks the production of 2HG by IDH2 mutants.sup.9,10. In a phase I/II clinical trial, enasidenib inhibited the production of 2HG and induced clinical responses in relapsed or refractory IDH2-mutant AML.sup.11. Here we describe two patients with IDH2-mutant AML who had a clinical response to enasidenib followed by clinical resistance, disease progression, and a recurrent increase in circulating levels of 2HG. We show that therapeutic resistance is associated with the emergence of second-site IDH2 mutations in trans, such that the resistance mutations occurred in the IDH2 allele without the neomorphic R140Q mutation. The in trans mutations occurred at glutamine 316 (Q316E) and isoleucine 319 (I319M), which are at the interface where enasidenib binds to the IDH2 dimer. The expression of either of these mutant disease alleles alone did not induce the production of 2HG; however, the expression of the Q316E or I319M mutation together with the R140Q mutation in trans allowed 2HG production that was resistant to inhibition by enasidenib. Biochemical studies predicted that resistance to allosteric IDH inhibitors could also occur via IDH dimer-interface mutations in cis, which was confirmed in a patient with acquired resistance to the IDH1 inhibitor ivosidenib (AG-120). Our observations uncover a mechanism of acquired resistance to a targeted therapy and underscore the importance of 2HG production in the pathogenesis of IDH-mutant malignancies. A new mechanism of acquired clinical resistance in two patients with acute myeloid leukaemia driven by mutant IDH2 is described, in which a second-site mutation on the wild-type allele induces therapeutic resistance to IDH2 inhibitors., Author(s): Andrew M. Intlekofer [sup.1] [sup.2] [sup.3] [sup.4] , Alan H. Shih [sup.1] [sup.2] [sup.4] [sup.5] , Bo Wang [sup.1] [sup.2] [sup.6] , Abbas Nazir [sup.1] [sup.2] , Ariën S. [...]

Published
2018
Full Text
View/download PDF

16. JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition

Author

McKenney, Anna Sophia, Lau, Allison N., Somasundara, Amritha Varshini Hanasoge, Spitzer, Barbara, Intlekofer, Andrew M., Ahn, Jihae, Shank, Kaitlyn, Rapaport, Franck T., Patel, Minal A., Papalexi, Efthymia, Shih, Alan H., Chiu, April, Freinkman, Elizaveta, Akbay, Esra A., Steadman, Mya, Nagaraja, Raj, Yen, Katharine, Teruya-Feldstein, Julie, Wong, Kwok-Kin, Rampal, Raajit, Heiden, Matthew G. Vander, Thompson, Craig B., and Levine, Ross L.

Subjects
Gene mutation -- Health aspects, Tumors -- Genetic aspects -- Development and progression -- Care and treatment, Myeloproliferative disorders -- Genetic aspects -- Development and progression -- Care and treatment, Health care industry
Abstract

Patients with myeloproliferative neoplasms (MPNs) frequently progress to bone marrow failure or acute myeloid leukemia (AML), and mutations in epigenetic regulators such as the metabolic enzyme isocitrate dehydrogenase (IDH) are associated with poor outcomes. Here, we showed that combined expression of [Jak2.sup.V617F] and mutant [IDH1.sup.R132H] or [Idh2.sup.R140Q] induces MPN progression, alters stem/progenitor cell function, and impairs differentiation in mice. [Jak2.sup.V617F] [Idh2.sup.R140Q]-mutant MPNs were sensitive to small-molecule inhibition of IDH. Combined inhibition of JAK2 and IDH2 normalized the stem and progenitor cell compartments in the murine model and reduced disease burden to a greater extent than was seen with JAK inhibition alone. In addition, combined JAK2 and IDH2 inhibitor treatment also reversed aberrant gene expression in MPN stem cells and reversed the metabolite perturbations induced by concurrent JAK2 and IDH2 mutations. Combined JAK2 and IDH2 inhibitor therapy also showed cooperative efficacy in cells from MPN patients with both [JAK2.sup.mut] and [IDH2.sup.mut] mutations. Taken together, these data suggest that combined JAK and IDH inhibition may offer a therapeutic advantage in this high-risk MPN subtype., Introduction Myeloproliferative neoplasms (MPNs) are clonal myeloid malignancies characterized by somatic mutations acquired in hematopoietic stem/progenitor cells, which drive the expansion of 1 or more myeloid lineages. Although patients with [...]

Published
2018
Full Text
View/download PDF

17. Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting

Author

He, Jie, Abdel-Wahab, Omar, Nahas, Michelle K., Wang, Kai, Rampal, Raajit K., Intlekofer, Andrew M., Patel, Jay, Krivstov, Andrei, Frampton, Garrett M., Young, Lauren E., Zhong, Shan, Bailey, Mark, White, Jared R., Roels, Steven, Deffenbaugh, Jason, Fichtenholtz, Alex, Brennan, Timothy, Rosenzweig, Mark, Pelak, Kimberly, Knapp, Kristina M., Brennan, Kristina W., Donahue, Amy L., Young, Geneva, Garcia, Lazaro, Beckstrom, Selmira T., Zhao, Mandy, White, Emily, Banning, Vera, Buell, Jamie, Iwanik, Kiel, Ross, Jeffrey S., Morosini, Deborah, Younes, Anas, Hanash, Alan M., Paietta, Elisabeth, Roberts, Kathryn, Mullighan, Charles, Dogan, Ahmet, Armstrong, Scott A., Mughal, Tariq, Vergilio, Jo-Anne, Labrecque, Elaine, Erlich, Rachel, Vietz, Christine, Yelensky, Roman, Stephens, Philip J., Miller, Vincent A., van den Brink, Marcel R.M., Otto, Geoff A., Lipson, Doron, and Levine, Ross L.

Published
2016
Full Text
View/download PDF

18. Data from Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia

Author

Shih, Alan H., primary, Meydan, Cem, primary, Shank, Kaitlyn, primary, Garrett-Bakelman, Francine E., primary, Ward, Patrick S., primary, Intlekofer, Andrew M., primary, Nazir, Abbas, primary, Stein, Eytan M., primary, Knapp, Kristina, primary, Glass, Jacob, primary, Travins, Jeremy, primary, Straley, Kim, primary, Gliser, Camelia, primary, Mason, Christopher E., primary, Yen, Katharine, primary, Thompson, Craig B., primary, Melnick, Ari, primary, and Levine, Ross L., primary

Published
2023
Full Text
View/download PDF

19. Table S1 from Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers

Author

Glass, Jacob L., primary, Hassane, Duane, primary, Wouters, Bas J., primary, Kunimoto, Hiroyoshi, primary, Avellino, Roberto, primary, Garrett-Bakelman, Francine E., primary, Guryanova, Olga A., primary, Bowman, Robert, primary, Redlich, Shira, primary, Intlekofer, Andrew M., primary, Meydan, Cem, primary, Qin, Tingting, primary, Fall, Mame, primary, Alonso, Alicia, primary, Guzman, Monica L., primary, Valk, Peter J.M., primary, Thompson, Craig B., primary, Levine, Ross, primary, Elemento, Olivier, primary, Delwel, Ruud, primary, Melnick, Ari, primary, and Figueroa, Maria E., primary

Published
2023
Full Text
View/download PDF

20. Table S3 (part 3) from Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers

Author

Glass, Jacob L., primary, Hassane, Duane, primary, Wouters, Bas J., primary, Kunimoto, Hiroyoshi, primary, Avellino, Roberto, primary, Garrett-Bakelman, Francine E., primary, Guryanova, Olga A., primary, Bowman, Robert, primary, Redlich, Shira, primary, Intlekofer, Andrew M., primary, Meydan, Cem, primary, Qin, Tingting, primary, Fall, Mame, primary, Alonso, Alicia, primary, Guzman, Monica L., primary, Valk, Peter J.M., primary, Thompson, Craig B., primary, Levine, Ross, primary, Elemento, Olivier, primary, Delwel, Ruud, primary, Melnick, Ari, primary, and Figueroa, Maria E., primary

Published
2023
Full Text
View/download PDF

21. Data from Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers

Author

Glass, Jacob L., primary, Hassane, Duane, primary, Wouters, Bas J., primary, Kunimoto, Hiroyoshi, primary, Avellino, Roberto, primary, Garrett-Bakelman, Francine E., primary, Guryanova, Olga A., primary, Bowman, Robert, primary, Redlich, Shira, primary, Intlekofer, Andrew M., primary, Meydan, Cem, primary, Qin, Tingting, primary, Fall, Mame, primary, Alonso, Alicia, primary, Guzman, Monica L., primary, Valk, Peter J.M., primary, Thompson, Craig B., primary, Levine, Ross, primary, Elemento, Olivier, primary, Delwel, Ruud, primary, Melnick, Ari, primary, and Figueroa, Maria E., primary

Published
2023
Full Text
View/download PDF

22. Supplementary Figures from Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition

Author

Harding, James J., primary, Lowery, Maeve A., primary, Shih, Alan H., primary, Schvartzman, Juan M., primary, Hou, Shengqi, primary, Famulare, Christopher, primary, Patel, Minal, primary, Roshal, Mikhail, primary, Do, Richard K., primary, Zehir, Ahmet, primary, You, Daoqi, primary, Selcuklu, S. Duygu, primary, Viale, Agnes, primary, Tallman, Martin S., primary, Hyman, David M., primary, Reznik, Ed, primary, Finley, Lydia W.S., primary, Papaemmanuil, Elli, primary, Tosolini, Alessandra, primary, Frattini, Mark G., primary, MacBeth, Kyle J., primary, Liu, Guowen, primary, Fan, Bin, primary, Choe, Sung, primary, Wu, Bin, primary, Janjigian, Yelena Y., primary, Mellinghoff, Ingo K., primary, Diaz, Luis A., primary, Levine, Ross L., primary, Abou-Alfa, Ghassan K., primary, Stein, Eytan M., primary, and Intlekofer, Andrew M., primary

Published
2023
Full Text
View/download PDF

23. Supplementary Figures S1 - S9 from Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia

Author

Shih, Alan H., primary, Meydan, Cem, primary, Shank, Kaitlyn, primary, Garrett-Bakelman, Francine E., primary, Ward, Patrick S., primary, Intlekofer, Andrew M., primary, Nazir, Abbas, primary, Stein, Eytan M., primary, Knapp, Kristina, primary, Glass, Jacob, primary, Travins, Jeremy, primary, Straley, Kim, primary, Gliser, Camelia, primary, Mason, Christopher E., primary, Yen, Katharine, primary, Thompson, Craig B., primary, Melnick, Ari, primary, and Levine, Ross L., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Tables S1 - S2 from Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia

Author

Shih, Alan H., primary, Meydan, Cem, primary, Shank, Kaitlyn, primary, Garrett-Bakelman, Francine E., primary, Ward, Patrick S., primary, Intlekofer, Andrew M., primary, Nazir, Abbas, primary, Stein, Eytan M., primary, Knapp, Kristina, primary, Glass, Jacob, primary, Travins, Jeremy, primary, Straley, Kim, primary, Gliser, Camelia, primary, Mason, Christopher E., primary, Yen, Katharine, primary, Thompson, Craig B., primary, Melnick, Ari, primary, and Levine, Ross L., primary

Published
2023
Full Text
View/download PDF

25. Table S3 (part 1) from Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers

Author

Glass, Jacob L., primary, Hassane, Duane, primary, Wouters, Bas J., primary, Kunimoto, Hiroyoshi, primary, Avellino, Roberto, primary, Garrett-Bakelman, Francine E., primary, Guryanova, Olga A., primary, Bowman, Robert, primary, Redlich, Shira, primary, Intlekofer, Andrew M., primary, Meydan, Cem, primary, Qin, Tingting, primary, Fall, Mame, primary, Alonso, Alicia, primary, Guzman, Monica L., primary, Valk, Peter J.M., primary, Thompson, Craig B., primary, Levine, Ross, primary, Elemento, Olivier, primary, Delwel, Ruud, primary, Melnick, Ari, primary, and Figueroa, Maria E., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Methods, Figure Legends, Table Legends, Figures S1 - S5 from Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers

Author

Glass, Jacob L., primary, Hassane, Duane, primary, Wouters, Bas J., primary, Kunimoto, Hiroyoshi, primary, Avellino, Roberto, primary, Garrett-Bakelman, Francine E., primary, Guryanova, Olga A., primary, Bowman, Robert, primary, Redlich, Shira, primary, Intlekofer, Andrew M., primary, Meydan, Cem, primary, Qin, Tingting, primary, Fall, Mame, primary, Alonso, Alicia, primary, Guzman, Monica L., primary, Valk, Peter J.M., primary, Thompson, Craig B., primary, Levine, Ross, primary, Elemento, Olivier, primary, Delwel, Ruud, primary, Melnick, Ari, primary, and Figueroa, Maria E., primary

Published
2023
Full Text
View/download PDF

27. Supplementary Methods from Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition

Author

Harding, James J., primary, Lowery, Maeve A., primary, Shih, Alan H., primary, Schvartzman, Juan M., primary, Hou, Shengqi, primary, Famulare, Christopher, primary, Patel, Minal, primary, Roshal, Mikhail, primary, Do, Richard K., primary, Zehir, Ahmet, primary, You, Daoqi, primary, Selcuklu, S. Duygu, primary, Viale, Agnes, primary, Tallman, Martin S., primary, Hyman, David M., primary, Reznik, Ed, primary, Finley, Lydia W.S., primary, Papaemmanuil, Elli, primary, Tosolini, Alessandra, primary, Frattini, Mark G., primary, MacBeth, Kyle J., primary, Liu, Guowen, primary, Fan, Bin, primary, Choe, Sung, primary, Wu, Bin, primary, Janjigian, Yelena Y., primary, Mellinghoff, Ingo K., primary, Diaz, Luis A., primary, Levine, Ross L., primary, Abou-Alfa, Ghassan K., primary, Stein, Eytan M., primary, and Intlekofer, Andrew M., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Methods, Figure Legends from Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia

Author

Shih, Alan H., primary, Meydan, Cem, primary, Shank, Kaitlyn, primary, Garrett-Bakelman, Francine E., primary, Ward, Patrick S., primary, Intlekofer, Andrew M., primary, Nazir, Abbas, primary, Stein, Eytan M., primary, Knapp, Kristina, primary, Glass, Jacob, primary, Travins, Jeremy, primary, Straley, Kim, primary, Gliser, Camelia, primary, Mason, Christopher E., primary, Yen, Katharine, primary, Thompson, Craig B., primary, Melnick, Ari, primary, and Levine, Ross L., primary

Published
2023
Full Text
View/download PDF

29. Table S3 (part 2) from Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers

Author

Glass, Jacob L., primary, Hassane, Duane, primary, Wouters, Bas J., primary, Kunimoto, Hiroyoshi, primary, Avellino, Roberto, primary, Garrett-Bakelman, Francine E., primary, Guryanova, Olga A., primary, Bowman, Robert, primary, Redlich, Shira, primary, Intlekofer, Andrew M., primary, Meydan, Cem, primary, Qin, Tingting, primary, Fall, Mame, primary, Alonso, Alicia, primary, Guzman, Monica L., primary, Valk, Peter J.M., primary, Thompson, Craig B., primary, Levine, Ross, primary, Elemento, Olivier, primary, Delwel, Ruud, primary, Melnick, Ari, primary, and Figueroa, Maria E., primary

Published
2023
Full Text
View/download PDF

30. Supplemental Methods from Nitrogen Trapping as a Therapeutic Strategy in Tumors with Mitochondrial Dysfunction

Author

Madala, Hanumantha Rao, primary, Helenius, Iiro Taneli, primary, Zhou, Wen, primary, Mills, Evanna, primary, Zhang, Yiyun, primary, Liu, Yan, primary, Metelo, Ana M., primary, Kelley, Michelle L., primary, Punganuru, Surendra, primary, Kim, Kyung Bo, primary, Olenchock, Benjamin, primary, Rhee, Eugene, primary, Intlekofer, Andrew M., primary, Iliopoulos, Othon, primary, Chouchani, Edward, primary, and Yeh, Jing-Ruey Joanna, primary

Published
2023
Full Text
View/download PDF

31. Data from Nitrogen Trapping as a Therapeutic Strategy in Tumors with Mitochondrial Dysfunction

Author

Madala, Hanumantha Rao, primary, Helenius, Iiro Taneli, primary, Zhou, Wen, primary, Mills, Evanna, primary, Zhang, Yiyun, primary, Liu, Yan, primary, Metelo, Ana M., primary, Kelley, Michelle L., primary, Punganuru, Surendra, primary, Kim, Kyung Bo, primary, Olenchock, Benjamin, primary, Rhee, Eugene, primary, Intlekofer, Andrew M., primary, Iliopoulos, Othon, primary, Chouchani, Edward, primary, and Yeh, Jing-Ruey Joanna, primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figures from Nitrogen Trapping as a Therapeutic Strategy in Tumors with Mitochondrial Dysfunction

Author

Madala, Hanumantha Rao, primary, Helenius, Iiro Taneli, primary, Zhou, Wen, primary, Mills, Evanna, primary, Zhang, Yiyun, primary, Liu, Yan, primary, Metelo, Ana M., primary, Kelley, Michelle L., primary, Punganuru, Surendra, primary, Kim, Kyung Bo, primary, Olenchock, Benjamin, primary, Rhee, Eugene, primary, Intlekofer, Andrew M., primary, Iliopoulos, Othon, primary, Chouchani, Edward, primary, and Yeh, Jing-Ruey Joanna, primary

Published
2023
Full Text
View/download PDF

33. A Patient-Derived T-Cell Lymphoma Biorepository Uncovers New Pathogenetic Mechanisms and Host-Related Therapeutic Vulnerabilities

Author

Fiore, Danilo, primary, Cappelli, Luca Vincenzo, additional, Zhaoqi, Liu, additional, Kotlov, Nikita, additional, Sorokina, Maria, additional, Phillip, Jude, additional, Zumbo, Paul, additional, Yoffe, Liron, additional, Ghione, Paola, additional, Wang, Anqi, additional, Han, Xueshuai, additional, Chiu, William, additional, Fragliasso, Valentina, additional, Tabbò, Fabrizio, additional, Zamponi, Nahuel, additional, Kayembe, Clarisse, additional, Gaudiano, Marcello, additional, Machiorlatti, Rodolfo, additional, Astone, Giuseppina, additional, Cacciapuoti, Maria Teresa, additional, Patel, Sanjay, additional, Zammarchi, Francesca, additional, Zanettini, Claudio, additional, Queiroz, Lucio, additional, Nikitina, Anastasia, additional, Kudryashova, Olga, additional, Karelin, Anton, additional, Nikitin, Daniil, additional, Tychinin, Dmitry, additional, Postovalova, Ekaterina, additional, Bagaev, Alexander, additional, Svekolkin, Viktor, additional, Belova, Ekaterina, additional, Tikhonova, Katerina, additional, Degryse, Sandrine, additional, Novero, Domenico, additional, Ponzoni, Maurilio, additional, Tiacci, Enrico, additional, Falini, Brunangelo, additional, Song, Joo Y., additional, Khodos, Inna, additional, De Stanchina, Elisa, additional, Macari, Gabriele, additional, Cafforio, Luciana, additional, Gardini, Simone, additional, Piva, Roberto, additional, Medico, Enzo, additional, NG, Samuel Y., additional, Moskowitz, Allison, additional, Epstein, Zachary, additional, Intlekofer, Andrew M., additional, Ahmed, Dogan, additional, Martin, Peter, additional, Ruan, Jia, additional, Bertoni, Francesco, additional, Foà, Robin, additional, Brody, Joshua, additional, Osan, Jaspreet, additional, Santambrogio, Laura, additional, Betel, Doron, additional, Chan, John C., additional, Tam, Wayne, additional, Weinstock, David M., additional, Cerchietti, Leandro, additional, Rabadan, Raul, additional, Horwitz, Steven, additional, and Inghirami, Giorgio G.A., additional

Published
2023
Full Text
View/download PDF

35. Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

Author

Wills, Beatriz, primary, Ganesan, Nivetha, additional, Shah, Gunjan L., additional, Wong, Phillip, additional, Argyropoulos, Kimon V., additional, Sen, Filiz, additional, Dogan, Ahmet, additional, Straus, David J., additional, Noy, Ariela, additional, Kumar, Anita, additional, Schoder, Heiko, additional, Michaud, Laure, additional, Palomba, Maria Lia, additional, Falchi, Lorenzo, additional, Lahoud, Oscar B, additional, Hamlin, Paul A., additional, Yahalom, Joachim, additional, Johnson, William T., additional, Zelenetz, Andrew D., additional, Intlekofer, Andrew M., additional, Owens, Colette, additional, Batlevi, Connie Lee, additional, Hamilton, Audrey, additional, Caron, Philip C, additional, Horwitz, Steven M., additional, Galasso, Natasha, additional, Hancock, Helen, additional, Davey, Theresa, additional, Santarosa, Alayna, additional, Perez, Leslie, additional, Capadona, Charisse, additional, Munayirji, Brittney, additional, Matasar, Matthew J., additional, Pongas, Georgios, additional, Casper, Ellie, additional, Salles, Gilles, additional, Moskowitz, Craig H., additional, Vardhana, Santosha, additional, and Moskowitz, Alison J., additional

Published
2022
Full Text
View/download PDF

36. Molecular Profiling across Lymphoma Subtypes Using MSK-Impact Next Generation Sequencing

Author

Batlevi, Connie Lee, primary, Drill, Esther, additional, Okwali, Michelle, additional, Ptashkin, Ryan, additional, Caron, Philip C, additional, Epstein-Peterson, Zachary D., additional, Falchi, Lorenzo, additional, Hamilton, Audrey, additional, Hamlin, Paul A., additional, Horwitz, Steven M., additional, Intlekofer, Andrew M., additional, Johnson, William T., additional, Khan, Niloufer, additional, Kumar, Anita, additional, Lue, Jennifer Kimberly, additional, Matasar, Matthew J., additional, Moskowitz, Alison J., additional, Noy, Ariela, additional, Owens, Colette, additional, Palomba, Maria Lia, additional, Straus, David J., additional, Vardhana, Santosha, additional, Zelenetz, Andrew D., additional, Arcila, Maria E., additional, Dogan, Ahmet, additional, Seshan, Venkatraman, additional, Salles, Gilles, additional, Zehir, Ahmet, additional, and Younes, Anas, additional

Published
2022
Full Text
View/download PDF

37. Characterization of a Large Cohort of Patients with Nodal Marginal Zone Lymphoma Shows Prolonged Survival, Time-to-Treatment, and Time-to-Transformation

Author

Stuver, Robert, primary, Drill, Esther, additional, Qualls, David, additional, Okwali, Michelle, additional, Batlevi, Connie Lee, additional, Caron, Philip C, additional, Epstein-Peterson, Zachary D., additional, Falchi, Lorenzo, additional, Hamilton, Audrey, additional, Hamlin, Paul A., additional, Horwitz, Steven M., additional, Intlekofer, Andrew M., additional, Johnson, William T., additional, Khan, Niloufer, additional, Lahoud, Oscar B, additional, Lue, Jennifer Kimberly, additional, Matasar, Matthew J., additional, Moskowitz, Alison J., additional, Noy, Ariela, additional, Palomba, M.Lia, additional, Vardhana, Santosha, additional, Zelenetz, Andrew D., additional, Salles, Gilles, additional, and Straus, David J., additional

Published
2022
Full Text
View/download PDF

38. Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay

Author

Intlekofer, Andrew M., Joffe, Erel, Batlevi, Connie L., Hilden, Patrick, He, Jie, Seshan, Venkatraman E., Zelenetz, Andrew D., Palomba, M. Lia, Moskowitz, Craig H., Portlock, Carol, Straus, David J., Noy, Ariela, Horwitz, Steven M., Gerecitano, John F., Moskowitz, Alison, Hamlin, Paul, Matasar, Matthew J, Kumar, Anita, van den Brink, Marcel R., Knapp, Kristina M., Pichardo, Janine D., Nahas, Michelle K., Trabucco, Sally E., Mughal, Tariq, Copeland, Amanda R., Papaemmanuil, Elli, Moarii, Mathai, Levine, Ross L., Dogan, Ahmet, Miller, Vincent A., and Younes, Anas

Published
2018
Full Text
View/download PDF

39. Mitonuclear genotype remodels the metabolic and microenvironmental landscape of Hürthle cell carcinoma

Author

Ganly, Ian, primary, Liu, Eric Minwei, additional, Kuo, Fengshen, additional, Makarov, Vladimir, additional, Dong, Yiyu, additional, Park, Jinsung, additional, Gong, Yongxing, additional, Gorelick, Alexander N., additional, Knauf, Jeffrey A, additional, Benedetti, Elisa, additional, Tait-Mulder, Jacqueline, additional, Morris, Luc G.T., additional, Fagin, James A., additional, Intlekofer, Andrew M, additional, Krumsiek, Jan, additional, Gammage, Payam A., additional, Ghossein, Ronald, additional, Xu, Bin, additional, Chan, Timothy A., additional, and Reznik, Ed, additional

Published
2022
Full Text
View/download PDF

43. GCN2 kinase activation by ATP-competitive kinase inhibitors

Author

Tang, Colin P., primary, Clark, Owen, additional, Ferrarone, John R., additional, Campos, Carl, additional, Lalani, Alshad S., additional, Chodera, John D., additional, Intlekofer, Andrew M., additional, Elemento, Olivier, additional, and Mellinghoff, Ingo K., additional

Published
2021
Full Text
View/download PDF

45. Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

Author

Moskowitz, Alison J., primary, Shah, Gunjan, additional, Schöder, Heiko, additional, Ganesan, Nivetha, additional, Drill, Esther, additional, Hancock, Helen, additional, Davey, Theresa, additional, Perez, Leslie, additional, Ryu, Sunyoung, additional, Sohail, Samia, additional, Santarosa, Alayna, additional, Galasso, Natasha, additional, Neuman, Rachel, additional, Liotta, Brielle, additional, Blouin, William, additional, Kumar, Anita, additional, Lahoud, Oscar, additional, Batlevi, Connie L., additional, Hamlin, Paul, additional, Straus, David J., additional, Rodriguez-Rivera, Ildefonso, additional, Owens, Colette, additional, Caron, Philip, additional, Intlekofer, Andrew M., additional, Hamilton, Audrey, additional, Horwitz, Steven M., additional, Falchi, Lorenzo, additional, Joffe, Erel, additional, Johnson, William, additional, Lee, Christina, additional, Palomba, M. Lia, additional, Noy, Ariela, additional, Matasar, Matthew J., additional, Pongas, Georgios, additional, Salles, Gilles, additional, Vardhana, Santosha, additional, Sanin, Beatriz Wills, additional, von Keudell, Gottfried, additional, Yahalom, Joachim, additional, Dogan, Ahmet, additional, Zelenetz, Andrew D., additional, and Moskowitz, Craig H., additional

Published
2021
Full Text
View/download PDF

47. Distinct Patterns of CD4+ and CD8+ T-Cell Clonal Expansion Enable Broad Clinical Responses to Pembrolizumab + GVD in Patients with Relapsed Hodgkin Lymphoma

Author

Wills, Beatriz, Rahman, Jahan, Ganesan, Nivetha, Shah, Gunjan L., Noy, Ariela, Schoder, Heiko, Yahalom, Joachim, Kumar, Anita, Falchi, Lorenzo, Hamlin, Paul A., Palomba, Maria Lia, Johnson, William, Intlekofer, Andrew M., Caron, Philip, Davey, Theresa, Hancock, Helen, Galasso, Natasha, Munayirji, Brittney, Hui Lin, Ya, Santarosa, Alayna, Casper, Ellie, Pongas, Georgio, Zelenetz, Andrew D., Moskowitz, Craig H., Salles, Gilles, Vardhana, Santosha A, and Moskowitz, Alison

Published
2023
Full Text
View/download PDF

48. Infectious Complications in Patients with Relapsed or Refractory (R/R) Non-Hodgkin's Lymphoma (NHL) Treated with the Anti-CD20xCD3 Bispecific Antibody (BsAb) Mosunetuzumab

Author

Shahid, Zainab, Okwali, Michelle, Joseph, Ashlee, Seo, Susan K., Lue, Jennifer Kimberly, Boardman, Alexander P., Caron, Philip, David, Kevin A., Epstein-Peterson, Zachary D., Ghione, Paola, Hamlin, Paul A., Horwitz, Steven M., Intlekofer, Andrew M., Johnson, William, Kumar, Anita, Moskowitz, Alison, Noy, Ariela, Owens, Colette, Palomba, Maria Lia, Stuver, Robert, Torka, Pallawi, Vardhana, Santosha A, Zelenetz, Andrew D., Salles, Gilles, and Falchi, Lorenzo

Published
2023
Full Text
View/download PDF

49. Predicting Toxicities in Older Adults with Non-Hodgkin Lymphoma (NHL) Receiving Systemic Chemotherapy: A Prospective Geriatric Assessment (GA) Study

Author

Torka, Pallawi, Drill, Esther, Ganesan, Nivetha, Oliveros, Mayan, Boardman, Alexander P., Caron, Philip, David, Kevin A., Epstein-Peterson, Zachary D., Falchi, Lorenzo, Ghione, Paola, Horwitz, Steven M., Intlekofer, Andrew M., Johnson, William, Kumar, Anita, Lue, Jennifer Kimberly, Moskowitz, Alison, Noy, Ariela, Owens, Colette, Palomba, Maria Lia, Stuver, Robert, Vardhana, Santosha A, Zelenetz, Andrew D., Salles, Gilles, and Hamlin, Paul A.

Published
2023
Full Text
View/download PDF

50. Clinical Characteristics and Outcomes of Limited Stage High Grade B-Cell Lymphoma with MYC/BCL2 and/or BCL6 Rearrangements: A Single Center Experience

Author

Lue, Jennifer Kimberly, Luttwak, Efrat, Caron, Philip, Boardman, Alexander P., David, Kevin A., Rivas-Delgado, Alfredo, Epstein-Peterson, Zachary D., Falchi, Lorenzo, Ghione, Paola, Hamlin, Paul A., Horwitz, Steven M., Intlekofer, Andrew M., Johnson, William, Kumar, Anita, Moskowitz, Alison, Noy, Ariela, Palomba, Maria Lia, Stuver, Robert, Torka, Pallawi, Vardhana, Santosha A, Zelenetz, Andrew D., Zhang, Yanming, Galera, Pallavi, Dogan, Ahmet, Aypar, Umut, and Salles, Gilles

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results